Correction: Bile Acid Metabolism-Based Integrative Subtyping Reveals CLCA1, UGT2A3, and ZG16 as Indicators of Immune Dysfunction and Adverse Outcomes in Colorectal Cancer

Overview

This correction addresses an error in the funding statement of the original article, clarifying that the Sichuan Science and Technology Program provided support for the research.

Background

Colorectal cancer (CRC) is a significant health concern, with various molecular markers being investigated for their prognostic value. Understanding the role of bile acid metabolism in CRC can provide insights into immune dysfunction.

Data Highlights

No numerical or trial data is presented in the correction article.

Key Findings

• The correction clarifies the funding source for the study.
• CLCA1, UGT2A3, and ZG16 are identified as indicators of immune dysfunction in colorectal cancer.
• Integrative subtyping may enhance understanding of CRC outcomes.
• Accurate reporting of funding sources is essential for research integrity.

Clinical Implications

Accurate funding disclosures are important for the credibility of research findings.

Conclusion

The correction emphasizes the accurate funding acknowledgment in research.

Related Resources & Content

1. Feng L, Wang M, Li X, et al., Front. Oncol., 2026 -- Correction: Bile Acid Metabolism-Based Integrative Subtyping Reveals CLCA1, UGT2A3, and ZG16 as Indicators of Immune Dysfunction and Adverse Outcomes in Colorectal Cancer
2. Frontiers in Medicine — Primary sclerosing cholangitis complicated with ulcerative colitis and double gene mutations of UGT1A1 and SLC25A13: a case report
3. Journal of Crohn's and Colitis — T-cell branched glycosylation as a mediator of colitis-associated colorectal cancer progression: a potential new risk biomarker in inflammatory bowel disease
4. the asco post — Integrated Clinical-Molecular Classification of Colorectal Liver Metastases
5. Identification of Colorectal Cancer Subtypes and Development of a Risk Model Utilizing Cholesterol Synthesis-Related Genes for Prognostic Prediction and Immunotherapy Guidance
6. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
7. FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation | FDA
8. Frontiers | Interplay between bile acids, gut microbiota, and the tumor immune microenvironment: mechanistic insights and therapeutic strategies